![Michel Drouin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michel Drouin
Career history of Michel Drouin
Former positions of Michel Drouin
Companies | Position | Start | End |
---|---|---|---|
MIRATI THERAPEUTICS | Corporate Officer/Principal | - | 2009-07-08 |
Aur Resources, Inc.
![]() Aur Resources, Inc. Other Metals/MineralsNon-Energy Minerals Aur Resources, Inc. is a Canadian-based, international mining company active in the acquisition, exploration, development and mining of mineral properties with a strong emphasis on copper. Over 95% of Aur’s revenue comes from the production of copper at its Quebrada Blanca, Andacollo and Louvicourt Mines. Aur is currently developing its Duck Pond copper-zinc deposit for production and conducting feasibility studies with a view to potentially developing the Andacollo primary copper deposit for production | Corporate Officer/Principal | - | 2009-01-21 |
Statistics
International
Canada | 2 |
United States | 2 |
Operational
Corporate Officer/Principal | 2 |
Sectoral
Non-Energy Minerals | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Aur Resources, Inc.
![]() Aur Resources, Inc. Other Metals/MineralsNon-Energy Minerals Aur Resources, Inc. is a Canadian-based, international mining company active in the acquisition, exploration, development and mining of mineral properties with a strong emphasis on copper. Over 95% of Aur’s revenue comes from the production of copper at its Quebrada Blanca, Andacollo and Louvicourt Mines. Aur is currently developing its Duck Pond copper-zinc deposit for production and conducting feasibility studies with a view to potentially developing the Andacollo primary copper deposit for production | Non-Energy Minerals |
Mirati Therapeutics, Inc.
![]() Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Michel Drouin
- Experience